tirzepatide weight loss percentage surmount trials Semaglutide vs. for Obesity SURMOUNT-3: Tirzepatide shows total mean

Mistake 3: not verifying compounded concentration We have covered this but it bears repeating

The medication that produces more weight loss actually had fewer people quitting due to stomach problems

A., Alegria, J

One of the most important is GLP-1 (glucagon-like peptide-1), which slows digestion, reduces appetite, and helps the pancreas release insulin

Some states may cover Mounjaro for diabetes, but Zepbound is rarely covered under Medicaid, even for approved obesity-related uses

(A different version of tirzepatide, Mounjaro, was approved by the FDA in May 2022 for type 2 diabetes management in adults, as a way to improve blood sugar when combined with diet and exercise.) In December 2024, Zepbound was also approved for the treatment of moderate to severe obstructive sleep apnea in adults with obesity